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Abstract
Background: To gain a better understanding of the effects of therapeutic agents on the tumor
microenvironment in invasive cancers, we developed a co-culture model from an invasive lobular
carcinoma. Tumor cells expressing HER2/neu organize in nests surrounded by alpha-Smooth
Muscle Actin (α-SMA) expressing tumor stroma to resemble the morphology of an invading tumor.
This co-culture, Mammary Adenocarcinoma Model (MAM-1) maintains a 1:1 ratio of HER2/neu
positive tumor cells to α-SMA-reactive stromal cells and renews this configuration for over 20
passages in vitro.
Methods: We characterized the cellular elements of the MAM-1 model by microarray analysis,
and immunocytochemistry. We developed flow cytometric assays to evaluate the relative
responses of the tumor and stroma to the tyrosine kinase inhibitor, Iressa.
Results: The MAM-1 gene expression profile contains clusters that represent the ErbB-2 breast
cancer signature and stroma-specific clusters associated with invasive breast cancers. The stability
of this model and the ability to antigenically label the tumor and stromal fractions allowed us to
determine the specificity of Iressa, a receptor tyrosine kinase inhibitor, for targeting the tumor cell
population. Treatment resulted in a selective dose-dependent reduction in phospho-pMEK1/2 and
pp44/42MAPK in tumor cells. Within 24 h the tumor cell fraction was reduced 1.9-fold while the
stromal cell fraction increased >3-fold, consistent with specific reductions in phospho-pp44/42
MAPK, MEK1/2 and PCNA in tumor cells and reciprocal increases in the stromal cells. Erosion of
the tumor cell nests and augmented growth of the stromal cells resembled a fibrotic response.
Conclusion: This model demonstrates the specificity of Iressa for HER2/neu expressing tumor
cells versus the tumor associated myofibroblasts and is appropriate for delineating effects of
therapy on signal transduction in the breast tumor microenvironment and improving strategies that
can dually or differentially target the tumor and stromal elements in the microenvironment.

Background
The development of targeted therapies for the specific
inactivation of receptor tyrosine kinase oncogenes
involved in tumor initiation and progression has lead to

the ability to target signal transduction as a modality for
cancer treatment and prevention [1,2]. ZD1839 (gefitinib,
Iressa®), an orally active, selective EGFR-Tyrosine Kinase
Inhibitor (TKI) that blocks signal transduction pathways
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implicated in proliferation and survival of cancer cells and
other host-dependent processes that promote cancer
growth [3,4]. To date, we have already demonstrated the
efficacy of Iressa against mammary and salivary gland
tumor cell lines derived from transgenic mice that overexpress the activated rat HER2/neu [5,6]. These studies
focused mainly on the direct effects of Iressa on tumor
cells. More recently, we have determined that Iressa can
also prevent the outgrowth and progression of mammary
and salivary gland cancers from early hyperplasias [7].
During these studies, we observed significant changes in
the microenvironment as a result of treatment. It has been
widely recognized that the tumor microenvironment
plays a major role in dictating tumor behavior and progression as well as response to therapy. To better define,
characterize and understand the effects of Iressa on the
tumor and its microenvironment we developed a stable
model of HER2/neu positive mammary tumor cells in coculture with alpha-Smooth Muscle Actin (α-SMA)-positive stromal cells that recapitulate the microenvironment
of an invasive carcinoma.
Several organotypic breast cancer models and co-cultures
have been described. These include admixtures of tumor
cells and fibroblasts or stromal cells [8-10], mammary
tumor cells grown as spheroids [11] or 3-dimensional
scaffolds [12], organ cultures [13] and orientated lumen
forming acinar cultures [14,15]. These can be laborious to
maintain and difficult to analyze without specialized reagents and equipment. We have developed a self-renewing
model that circumvents some of these technical barriers
and has proven to be stable, reliable and user friendly. We
have identified several advantages to the Mammary Adenocarcinoma Model (MAM-1) for screening preventive and
therapeutic agents, emphasizing the need to evaluate therapies in the context of homotypic microenvironment.
MAM-1 is immortal and faithfully recapitulates the morphology of invasive carcinomas that arise in BALB-NeuT
transgenic mice, a model for HER2/neu driven lobular
carcinoma [16]. MAM-1 grows rapidly in vitro and in vivo
and maintains a 1:1 tumor-to-stroma ratio with routine
passaging. This ratio can be manipulated with differential
trypsinizations. This configuration is stable for over 20
passages. In MAM-1 there is no need for separate cultures,
special media or culture conditions. MAM-1 can be used
to test any agent or type of therapy, especially HER2 and
stroma targeted therapies including biological and immunotherapies. Using MAM-1 treatment effects can be followed by out growth assays in vitro and in vivo (residual
tumorigenic potential) in BALB/c mice. A key advantage
to MAM-1 is the ability to simultaneously evaluate tumor
cells and stromal cells using convenient markers (i.e., αSMA, HER2) that are stable and suitable for flow cytometry (FACs) and immunofluorescent imaging. Further-
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more, cells can be fractioned, based on these stable
markers, to generate lysates for IP, Western blot, and multiplex bead arrays or generate RNA and DNA for microarray and methylation analyses. Finally, MAM-1 is suitable
for use in assays that evaluate invasive and angiogenic
potential of cells.
In this paper we describe the development of the MAM-1
co-culture model and methods for manipulating and analyzing it to evaluate mechanism(s) of the receptor tyrosine
kinase inhibitor, Iressa. We further resolve a dynamic reciprocity between tumor and stromal cell populations during growth and treatment.

Methods
BALB-NeuT Transgenic animals
Two stock BALB-NeuT transgenic males were obtained
through collaboration with Dr. Guido Forni. The BALBNeuT strain originated from a transgenic CD1 randombred breeder male mouse (no. 1330) carrying the mutated
rat HER2/neu oncogene driven by the MMTV promoter
[16]. The mutated gene encodes a single point mutation
that replaces the valine residue at position 664 in the
transmembrane (TM) domain of p185/neu with glutamic
acid. This mutation promotes p185/neu homo- and heterodimerization and transforms the HER2/neu protooncogene into a dominant transforming oncogene. In these
studies animals were used for tissue harvest only. Nonetheless, all animal research was conducted following an
approved protocol filed with the Animal Investigation
Committee at Wayne State University that oversees the
Division of Laboratory Animal Resources (DLAR) at this
institution in strict accordance with NIH guidelines.
Iressa™ and cell lines
"Iressa™" (Zeneca Pharmaceuticals Macclesfield, Cheshire) ZD1839, 4-(3-chloro-4-fluoroanilino)-7-methoxy-6(3-morpholinopropoxy) quinazoline was suspended in
DMSO at 10 mM and stored at -20°C until use. Dilutions
were prepared in culture medium to make final concentrations ranging from 0.25–10 µM. The Bam1a cell line has
been previously described and characterized [6].
Establishment and Maintenance of the MAM-1 co-culture
Model
The MAM-1 co-culture model was established from a
BALB-NeuT transgenic mouse with an advanced mammary gland lobular carcinoma involved with hemorrhage.
The tissue was removed asceptically and rinsed extensively
in sterile PBS. The tissue was minced and dissociated
briefly with collagenase. Cells were washed extensively
with complete medium and explanted into tissue culture
media. Cultures grew in an organization of tumor cell
nests surrounded by myofibroblasts and maintained a
consistent 1:1 ratio of tumor cells to stromal cells. These
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cultures were maintained in vitroin Dulbecco's modified
Eagle's medium (DMEM) with high glucose and supplemented with 10% heat inactivated Serum Supreme (BioWhittaker, St. Louis, MO), 0.5 mM sodium pyruvate, 2
mM L-glutamate, 0.1 mM MEM nonessential amino acids,
100 units/ml penicillin and 100 µg/ml streptomycin and
10 µM Dexamethasone. Inclusion of dexamethasone,
impairs the growth of contaminating fibroblasts and
endothelial cells with limited proliferative and immortalization potential. Cells were cultured in 10% CO2, media
was changed every 3–4 days until confluence and split at
a 1:5 ratio for routine passaging. -Co-cultures can be
expected to maintain a 1:1 ratio during active growth. This
ratio may be altered if cultures are kept beyond confluence
when stromal cells continue to grow. At time of passage,
the majority of stromal cells are collected separately by a
brief trypsinization. The remaining co-culture is further
trypsinized and monodispersed and collected separately.
Both collections are counted by hemacytometer which
readily allows for distinguishing between the tumor
(small) and stromal (large) cells. If need be, the cell ratios
can be readjusted to accommodate the desired 1:1 ratio.
All in vitro data presented in this manuscript used MAM-1
between passages 5–20.
Immunohistochemistry
At time of necropsy, tumor tissues were fixed in 10% neutral buffered formalin and paraffin embedded using
standard histochemical techniques. Blocks were sectioned
4-micron. Tissue sections were stained with Hematoxylin
and Eosin for basic histological evaluation. For immunodetection of tissue antigens, histological grade primary
antibodies were applied to the samples and incubated
according to manufacturer's recommendation: HER2,
PAD: Z4881, cat# 08-1204 2nd Gen; PCNA, cat# 08-1110
(Zymed, South San Francisco, CA), PCNA Ab-1 clone
(PC10) cat# MS-106-R7; Actin, Smooth Ab-1 (1A4) cat#
MS-113-R7 (Neomarkers, Fremont, CA). Samples were
washed and labeled using the SuperPicTure™ Polymer
Detection Kit, cat#87-9263; Zymed), developed with DAB
Substrate and counterstained with hematoxylin. Samples
were evaluated using a Zeiss microscope and images were
collected through a Sony 970 CCD camera interfaced with
the MCID5+ imaging software package. Alternatively
images were collected using a Nikon inverted microscope
equipped with a SPOT digital cooled camera and imaging
software. Stained sections were evaluated by a board certified pathologist to generate descriptions.
Flow cytometric analysis of MAM-1 co-cultures
A variety of antibodies were used for flow cytometric analyses. Selection of antibody combinations was based on
fixation, host species, avidity/affinity for specific epitopes
and antigen density. Antibodies used in these studies
included: antibody to the rat Her2/neu (Ab-9, clone B10,

http://www.biomedcentral.com/1471-2407/8/119

cat# MS-326); erbB-2 (Ab-15, clone 3B5, cat# MS-599,
NeoMarkers, Fremont, CA). CD24 (M1/69) sc-19651-PE;
CD29 (Integrin β1 (HMβ1-1) sc-19656-PE; p-c-Jun
(Ser63)-PE (KM-1) sc-822-PE all from Santa Cruz Biotechnology, Santa Cruz, CA. Ready to use histological grade
antibodies that were also used on formaldehyde fixed
samples prepped for flow cytometry or immunofluorescence included: (HER2, PAD: Z4881, cat# 08-1204 2nd
Gen; PCNA, cat# 08-1110 Zymed, South San Francisco,
CA). or PCNA Ab-1 clone (PC10) cat# MS-106-R7; Actin,
Smooth Ab-1 (1A4) cat# MS-113-R7 or cat# RB-9010-R7,
Neomarkers, Fremont, CA. Phospho-specific antibodies
from Cell Signaling Technologies, (Beverly, MA) used in
FACS and Immunofluorescence included: p-p44/42 MAP
kinase (Thr202/Tyr204, #9101), p-MEK ½ (Ser217/221.
#9121)
Routine cell surface staining of fresh cell cultures was as
previously described [5]. For evaluation of intracellular
antigens, MAM-1 were plated in 6 well tissue cultures
plates to produce a confluent, organized co-culture (1:1
tumor to stroma cell ratio) within 2–3 days of seeding.
Cells were harvested at specific time points after treatment
with trypsin/EDTA, quenched with complete medium
and collected by centrifugation. Pellets were resuspended
in 1 mL of PBS and monodispersed by passing through a
small bore pipet. Cells were fixed by titrating in 5% Formaldehyde to a final concentration of 1%, incubated at
37°C for 10 minutes, then chilled on ice for 2 minutes.
Absolute, ice-cold (-20°C) methanol was added while
vortexing to a final concentration of 90%. Samples were
vortexed rigorously and incubated on ice for 30 minutes.
Cells were collected by centrifugation and blocked for 30
minutes on ice with chilled FACscan buffer (PBS supplemented with 2% serum and 0.1% sodium azide). Cells
were washed once with fresh FACscan buffer prior to the
addition of primary antibodies or isotype controls and
stained overnight at 4°C in accordance to the manufacture's guidelines. Cells were washed twice and stained
with the appropriate -PE or -FITC conjugated secondary
antibodies: goat anti-mouse IgG-PE, cat# 111-116-144;
donkey anti-rabbit IgG-FITC, cat#711-096-152; donkey
anti-mouse IgG-PE, cat# 715-116-150 (Jackson ImmunoResearch, West Grove, PA) at 1:50 to 1:200 on ice for 45
min. After staining, samples were washed twice with FACscan buffer, placed on ice and evaluated by flow cytometry
using the dual-color laser option (FL1 v. FL2) in the FACsCaliber. At least 20,000 events were collected for every
sample. Data were analyzed using WinMDI version 2.8
software. Importantly, all experiments were reproduced at
least three times using MAM-1 of different passage numbers and overlapping experimental treatments and time
points. The specificities of all stains were validated by
using various combinations of monoclonal and polyclonal antibodies for each antigen and different secondary
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labels. All phospho-specific markers and PCNA stains
were evaluated by direct reciprocal dual-staining for the
test antigen with in combination with antibodies to ErbB2
and α-SMA to verify that all ErbB-2 negative responses
were identical to α-SMA positive responses and vice versa.
Immunofluorescence
MAM-1 suspensions were plated on glass cover slips in 6
well plates in complete media and grown to 90–95% of
confluence and treated as described in the text. Following
treatment, cells were fixed and permeabilized by immersion in ice-cold 100% methanol and incubated at -20°C
for 10–20 min. Methanol was aspirated and cover slips
were air-dried, washed and blocked prior to administration of primary antibodies. Primary antibodies were
diluted and incubated on cover slips according to the recommendations for each specific antibody. Cover slips
were washed 4 times before adding the secondary FITC- or
TRITC-conjugated goat anti-mouse or rabbit IgG (cat#
115-096-071, 111-096-046, 111-116-144 or 115-116071; Jackson ImmunoResearch, West Grove, PA) antibodies diluted 1:50-1:200 in FACscan buffer. Samples were
incubated with secondary for 45 min. at room temperature in the dark. Stained cover slips were washed and
mounted in Fluorescent mounting media (cat# HT08,
Oncogene Science) containing DAPI for nuclear counterstaining. Slides were visualized at 100× under oil with a
Zeiss microscope equipped with a Sony 970 digital cooled
camera. Fluorescence photomicrographs were imaged
using MCID5+ software. Live cell images and phase contrast of cells fixed in 6-well culture dishes were evaluated
with a Nikon inverted microscope and imaged using the
attached SPOT digital cooled camera and imaging software.
Gene Expression Analysis
Total RNA was isolated from triplicate wells of Bam1a
cells [6] or MAM-1 co-cultures that were treated for 24 h
with complete media containing 0 or 1 µM Iressa. Total
RNA was isolated using RNeasy kit (Qiagen, Carlsbad,
CA) and sent to SuperArray Bioscience Corporation (Frederick, MD) and processed utilizing the GEArray Hybridization and Analysis Service and Agilent Mouse Genome
CGH Microarray 44A that has 43,000+ annotated gene
sequences with well-characterized genes represented by
1+ probes and cancer-relevant genes by 2+ probes. In
some comparisons Universal mouse RNA provided by
Agilent was also used in the analyses for normalization.
Three independent RNA preparations per condition were
analyzed on three separate chips and used to generate the
analysis report. To generate lists of highly expressed genes,
RNA from MAM-1 was labeled in red color (cy5), universal RNA was labeled in green (cy3). 1) In **treated vs
**control comparison, the treated is labeled in red color
(cy5), control is labeled in green color (cy3). Fold change

http://www.biomedcentral.com/1471-2407/8/119

(**treated/**control) = Normalized ratio value (cy5/
cy3); fold change cutoff >2 fold (up regulate) or < 1/2
(down regulate); confidence cutoff >0.95.

Results and Discussion
Histological analysis of the primary tumor tissue used to
derive MAM-1
The tumor was obtained from a BALB-NeuT transgenic
mouse bearing a lesion that involved a hemorrhage of the
#8 thoracic mammary gland. The pathology report
describes the tumor as forming a discrete nodule, most of
which is contained within a thin rim of collagen (pseudocapsule) with rare isolated acini penetrating it (Fig. 1A).
The tumor is made of epithelial cells, arranged in illdefined nests that are separated by fine fibrous septa. Discrete acini, delimiting central lumens, and filled with
lightly eosinophilic secretions, confer to these epithelial
nests a distinct overall, sieve-like (cribriform) configuration. Necrotic material and focally hemorrhage, frequently accumulates within the tumor, in a punctate
fashion (comedo-type necrosis). Tumor cells show
homogenous cytological features and only mild pleomorphism (Fig. 1B). They are polygonal, with a relatively low
N/C ratio, eosinophilic cytoplasm, round central nuclei
with finely dispersed chromatin and infrequent macronucleoli and undergo frequent mitoses. This description is
consistent with the morphology of the lobular carcinomas
that arise in BALB-NeuT transgenic mice [16].

The sample of this lesion that was explanted and processed for growth in vitro, demonstrates a significant stromal cell component (Fig. 1). By immunohistochemistry
we observed that HER2/neu staining was strong and
present in the majority of the tumor cells (Fig. 1C), in a
cytoplasmic and membranous distribution and that αSMA staining was strong and exclusively expressed in the
cytoplasm of the stromal cells that were involved in the
fibrous sheaths surrounding the tumor cell nests (Fig.
1D).
Growth and maintenance of MAM-1 explant cultures
In mice transgenic for the activated rat HER2/neu under
the MMTV promoter, expression of the oncogene in the
mammary gland epithelium gives rise to an alveolar type
of lobular carcinoma that requires an angiogenic switch
for tumor onset and progression to invasive cancer [16].
Coordinated epithelial-stromal interactions that are
required for mammary morphogenesis and development
are also critical for tumor progression in this model. In the
case of human breast cancers, stromal alterations are also
integral to the evolution and progression of breast cancer
[17,18].

Preservation of the breast cancer microenvironment is
critical for evaluating therapeutic agents especially when
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Histological
Figure 1 analysis of the primary tumor tissue used to derive MAM-1
Histological analysis of the primary tumor tissue used to derive MAM-1. The tumor was obtained from the #8 mammary gland of a BALB-NeuT transgenic mouse. A. Hematoxylin and Eosin staining revealed a prominent fibrovascular response
associated with the tumor (4×). The tumor forms a discrete nodule within a thin rim of collagen (pseudocapsule). The tumor is
made of epithelial cells, arranged in ill-defined nests (arrow) that are separated by fine fibrous septa. Discrete acini, delimiting
central lumens, and filled with lightly eosinophilic secretions, confer to these epithelial nests a distinct overall, sieve-like (cribriform) configuration. Necrotic material and focal hemorrhage accumulates within the tumor, in a punctate fashion (comedotype necrosis). B. Tumor cells show homogenous cytological features and only mild pleomorphism. They are polygonal, with a
relatively low N/C ratio, eosinophilic cytoplasm, round central nuclei with finely dispersed chromatin and infrequent macronucleoli and undergo frequent mitoses (40×). C. Immunohistochemical analysis of HER2/neu shows strong staining in the majority
of the tumor cells, in a cytoplasmic and membranous distribution. D. Immunohistochemical analysis for α-SMA detected strong
cytoplasmic staining associated exclusively with the stromal cells (arrow) surrounding the tumor cell nests. The antigens were
detected by DAB (brown) and nuclei counterstained with hematoxylin (blue). Images were photographed under 40× objective.
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designing modalities that target invasive disease. Thus, we
sought to establish a homotypic system representing invasive breast cancer by explanting the mammary tumor and
associated stromal cells to develop a co-culture model.
Upon explantation from the tumor, primary cultures that
grew in vitro produced a co-culture that organized as
multi-cell layered nests of tumor cells surrounded by concentric rings of stromal cells. These arrangements bear a
striking similarity to the morphology of the primary
tumor lesion (Fig. 2). This configuration was stable and
was able to renew itself under limiting cell dilutions, these
co-cultures were designated as MAM-1.
Passage of MAM-1 stock cultures at a 1:5 ratio maintained
this organized growth pattern to reproducibly generate cocultures that consisted of 50% tumor cells and 50% stromal cells. Cultures maintained in this way achieved 95%
confluence within 5–7 days reproducibly for out to 20
passages. There was a tendency for stromal cells to proliferate more rapidly. Excess stromal cell growth was controlled by a mild trypsinization that released the
superficial layer of stromal cells from the culture. At days
3–5 post-confluence, tumor cell nests formed spheroids
that eventually pinched off and were capable of re-establishing the MAM-1 configuration when plated on fresh tissue culture plastic. Thus, spheroid formation is a natural
progression in this co-culture model and does not require
the elaborate procedures or growth conditions described
for other model systems [8,11,12]. MAM-1 is also capable
of growth in soft agar. However, if not in association with
MAM-1 tumor cells, stromal cells will tend to form monolayers on top of or beneath the agar. One reason for the
faithful renewal of this self-contained co-culture model
can be attributed to the properties of syngeneic tumor
associated stromal cells which have a strong influence on
mammary tumor cell growth and gene expression
[8,11,18]. Further studies are underway, to establish the
genetic relationship between the cells of the stroma and
tumor (i.e. karyotype analysis) and to determine the
potential of each cell type to develop tumors in vivo.
Validation of tumor specific and stroma specific antigens in
explant cultures by Immunofluorescence and Flow
cytometry
As suggested by immunohistochemical analysis of the primary tumor (Fig. 1) we expected the tumor cells in these
co-cultures to express HER2/neu and the stromal cells to
express α-SMA. We observed that expression of HER2/neu
was exclusive to the tumor cell nests with a high level of
distribution in the membrane and cytoplasm (Fig. 2).
HER2/neu expression was at background level in the stromal cells, and α-SMA was strongly expressed in the cytoplasmic actin-based microfilaments exclusively in these
cells. In this co-culture setting, strong and consistent
expression of both antigens, tumor-associated HER2/neu
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and stromal-associated α-SMA were stable out to 20 passages. Using these two antigens as markers to identify and
separate tumor from stroma cells, we adapted our staining
method for flow cytometric analysis that would enable us
to evaluate responses in each cell type.
As shown in Fig. 3A, the MAM-1 co-culture is readily fractionated into a HER2/neu+, α-SMA-tumor subpopulation
that accounts for 50–55% of the culture, a HER2-, αSMA+ stromal cell population that accounts for 40–45%
of the culture, a HER2/neu+, α-SMA+ population which
may represent a stem cell or cells undergoing mesenchymal transition and typically accounts for 3–5% of the culture and finally a double negative population that appears
to represent a fibroblast population that typically
accounts for 3–5% of the culture.
Whether or not a "true" mammary stem cell exists in this
co-culture is under investigation. A variety of candidate
mammary stem cell markers are expressed by the different
subpopulations. In mature MAM-1 co-cultures we have
determined that the tumor cell population is HER2/neu+,
CD24lo/med, CD29hi, SMA- and the stromal population is
HER2/neu-, CD24neg, CD29hi, SMA+. Since CD24 negative, lo and hi populations correspond to nonepithelial,
basal/myoepithelial and luminal epithelial cells respective [19], we consider our "stromal" cells to be nonepithelial and our "tumor" cells to be a mixture of luminal and
basal/myoepithelial phenotypes. In so much as
CD24+CD29hi phenotype is enriched in its ability to
reconstitute the essential elements of the mammary
gland, a mammary tumor stem cell-like subpopulation
may be present in these MAM-1 cultures. Since the "oncogenic" activated rat HER2/neu genetic lesion is expressed
in the mammary stem cell of the donor BALB-NeuT transgenic mice, it is possible that this co-culture model may
support a limited degree of cell differentiation from a
stem-like progenitor that is in the HER2/neu positive subpopulation. Further support for a stem cell component in
this self-renewing co-culture model is provided by the
high level of CD44 in MAM-1 and enriched expression of
vimentin and cytokeratin 19 in MAM-1 compared to the
cloned Bam1a cell line described later.
Using flow cytometric analysis we were able to further
subfractionate the HER2/neu (tumor) population based
on their Forward Scatter Profile, which is an index of cell
size. These different size tumor cell subpopulations may
represent cells enriched at different phases of the cell
cycle, smaller cells tend to be enriched for cells in G0 and
larger cells tend to be enriched for cells in G2/M (not
shown). We typically observe an equal distribution of
small (S) and large (L) cell subpopulations in the mammary tumor cell fraction (Fig. 3B). We observed that the
larger cell population (L) had approximately >3-fold
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Figure 2, Piechocki
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2 of Tumor tissue morphology in vivo with Explants grown in vitro
Comparison of Tumor tissue morphology in vivo with Explants grown in vitro. In Vivo H&E (Top panel) is Hematoxylin and Eosin staining of the primary tumor lesion used for generating explant cultures and shows tumor cell nests in a
fibrofatty matrix within the breast stroma taken with a 10× objective (left) and 25× objective (right). In Vitro Phase Contrast
photomicrographs (Middle Panel) depict the growth and morphology of MAM-1 explant cultures in vitro. Photomicrographs
were taken with a (10×, left) or (20×, right) objective. Note in particular the morphological similarities between the explants
grown in vitro and resemblance to the tumor in vivo. In Vitro Immunofluorescence (Bottom Panel) of MAM-1 grown on coverslips and dual-stained for HER2/neu (FITC, green) and α-SMA (TRITC, red) and counterstained for DAPI depicting the nuclei
in blue. HER2/neu staining is strong and specific for tumor cells while α-SMA staining is exclusively associated with the cells
surrounding the tumor cell nests and localized to the actin-based cytoskeleton. Asterisk depicts nucleus of stromal cell for orientation.
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Figure 3, Piechocki
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Analysis of MAM-1 co-cultures. A. Density plot of MAM-1 co-culture stained for HER2/neu and α-SMA
Flow Cytometric Analysis of MAM-1 co-cultures. A. Density plot of MAM-1 co-culture stained for HER2/neu
and α-SMA. MAM-1 co-cultures were stained with the same ready-to-use, histological grade antibodies that were used for
IHC and IC to detect HER2, PAD: Z4881 and α-SMA, (1A4) in tissues. Primary antibodies were labeled with -PE and FITC conjugated secondaries as described in the methods. Quadrant analysis revealed that MAM-1 cultures consisted of 52% HER2/
neu+, α-SMA- tumor cells, 40% HER2/neu-, α-SMA+ stromal cells, a 5% population of HER2/neu-, α-SMA- cells and a 3% population of HER2/neu+, α-SMA+ cells which may represent cells undergoing epithelial-mesenchymal transition. At the right, Histogram analysis of the separate FL1 (top) and FL2 (bottom) events indicates 54% of the culture as positive for HER2/neu (top)
and 43% of cells as positive for α-SMA (bottom) which is consistent with the quadrant analysis. Filled peaks are specific antibody stained cells and open peaks represent background staining with the isotype control. B. Subpopulation analysis of Tumor
cell fractions in MAM-1 co-cultures based on Forward scatter profiles. Dot plot analysis of a-SMA-PE stained cells versus Forward scatter indicates the presence of two distinct subpopulations of different size in the a-SMA negative fraction labeled as S
(small) and L (large). Histogram analysis of these gated subpopulations (defined by the circles) for HER2/neu specific staining
indicates that the small population has lower levels of HER2/neu, a mean channel fluorescence of 110 compared to the large
population enriched in dividing cells, with a mean channel fluorescence of 366.
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higher level of HER2/neu expression on the cell surface. If
this subpopulation represents a high proportion of cells
in G2/M antigens and drug responses that are differentially sensitive to the phase of cell cycle can be detected/
identified in the different sized tumor subpopulations (by
forward scatter) and then confirmed and correlated with
further analysis of the cell cycle distribution. For example,
MAM-1 co-cultures that are treated for 1 hour with Iressa
show a redistribution of p-c-Jun (Ser63) to the nucleus
(Fig. 4A) and HER2/neu to the cytosol. In addition to
redistribution from the cytosol, there was an overall
decrease tumor cell associated phospho-c-Jun (i.e., in the
α-SMA negative cells) but not in the α-SMA positive stromal cells (Fig. 4B). The observed 45% decrease in overall
tumor cell phospho-c-Jun resulted from a 46% decrease
that corresponded to the small cells and a 38% decrease in
the large cells. Thus, small, non-dividing cells are about
20% more responsive to Iressa in terms of c-Jun phosphorylation. This further implies that large, dividing cells,
which are enriched in HER2/neu receptors (Fig. 3B) and
have a higher baseline level of phospho-c-Jun also have
transient resistance to Iressa at this stage of the cell cycle.
It has been widely documented that dividing cells often
have a higher level of intrinsic resistance to a variety of
chemotherapeutic agents.
The MAM-1 transcriptome has a genetic signature of
ErbB-2 breast cancers and desmoplasia observed in
invasive breast cancers
We defined the MAM-1 transcriptome of highly expressed
genes by comparing total RNA from a MAM-1 co-culture
to a commercial preparation of universal mouse RNA
which provides a balanced representation of normal and
cancerous mouse tissues and cell lines. We used a cutoff
value of >2-fold to be considered over-expressed and a p
value cutoff > .05. A comprehensive listing of >2,000
known genes generated in this comparison is provided
[see Additional file 1].

To identify genes associated with the tumor cell and stromal cell subpopulations in these cultures we compared
the gene expression profiles of the Bam1a cell line, a
cloned and characterized mammary carcinoma cell line
developed from a BALB-NeuT mouse [6] and MAM-1 cocultures. Bam1a was established from a soft agar colony
and found to be immortal in vitro and tumorigenic in
vivo and highly sensitive to Iressa and anti HER2/neu
antibodies both in vitro and in vivo [6]. We identified
clusters of genes that were highly expressed and common
to Bam1a and MAM-1 co-cultures or differentially
expressed between Bam1a and MAM-1. Table 1 is a representation of genes that are highly expressed by Bam1a and
MAM-1 and part of the "ErbB-2 Signature" that is associated with many ErbB-2 expressing breast cancers [20-23].
In most instances the relative expression level of these sig-

http://www.biomedcentral.com/1471-2407/8/119

nature genes was similar (within 2-fold) between Bam1a
and MAM-1. This two-fold difference is likely to represent
the dilution of tumor cell RNA with stromal cell RNA in
the MAM-1 co-culture.
Genes uniquely over-expressed by MAM-1 largely reflect
the stromal signature of this breast cancer co-culture system. A select list of ~563 differentially expressed genes is
provided [see Additional file 2]. We considered only differences greater than 3-fold to compensate for the dilution
of tumor and stroma specific RNA in the MAM-1 cultures
when compared to the cloned cell line, Bam1a. Certain
genes that are uniquely over-expressed in Bam1a are likely
to reflect the influence of co-culture on the gene-expression patterns. Paradoxically, for example, we observe >25fold higher expression of EPSTI1 in Bam1a compared to
MAM-1, which contradicts what is typically observed and
expected [12]. A majority of the genes that are overexpressed in MAM-1 have been identified in tumor associated fibroblasts and stromal cells and represent genes
involved in the fibrotic response and basement membrane synthesis [24,25]. In particular, collagen genes
involved in fibrosis and contraction and growth factors
that stimulate the fibrotic response. In addition, genes
involved in remodeling the extracellular matrix, including
ADAM and MMP family members are highly represented.
When we compared genes differentially expressed
between Bam1a and MAM-1 to genes clusters used to
determine the stromal signatures of breast cancers, we
found that relative to Bam1a, MAM-1 over-expressed 70%
of the genes associated with the desmoid-type fibromatosis signature described by West et al. [24] including
WISP2, COL1A1, COL5A1, COL3A1, COL6A1, MMP23,
MMP19, CNN1, CTGF, ADAM19, FBN1 and ADAM12
(Table 2). This cluster of stroma specific genes, also identifies subgroups of breast carcinomas with a more favorable outcome when compared to the solitary fibrous tumor
cluster [24] Further analyses revealed similarities between
MAM-1 and an invasion specific cluster that is associated
with the desmoplastic response to invading breast cancer
[25] (Table 2). In particular, we observe >20-fold overexpression of COL1A1, IGFBP7 and SPARC in MAM-1
which are correlated with panstromal and juctatumoral
stromal cell responses involved in matrix remodeling and
angiogenesis, respective. These data are consistent with
the histological features of the primary lesion used to
establish MAM-1 and demonstrate the preserved expression of invasion specific genes in the MAM-1 co-culture.
We also observed upregulation of a variety of stroma specific genes associated with tumor progression, invasion
and the malignant phenotype in MAM-1. These include,
MMP2 [10,18]ADAM12 [26], HAS2, [27] and CLIC4
[28,29]. Others have also demonstrated that heterologous
co-cultures of breast tumor cells with tumor-derived

Page 9 of 22
(page number not for citation purposes)

BMC Cancer 2008, 8:119

http://www.biomedcentral.com/1471-2407/8/119

A

Figure 4, Piechocki
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(Ser63) levels and subcellular distribution in MAM-1 co-cultures treated with Iressa by A. ImmunofluoresEvaluation of p-c-Jun (Ser63) levels and subcellular distribution in MAM-1 co-cultures treated with Iressa by A.
Immunofluorescence and B. Flow Cytometry. MAM-1 were subcultured on coverslips or in 6-well plates and grown to
~95% confluence and then treated by replacing the conditioned media with fresh media that contained diluent (.001% DMSO,
Control) or 1 µM Iressa for 1 hour prior to fixing and evaluation as described in the methods. A. Immunofluorescent photomicrographs were taken with the 100× objective under oil immersion of cells that were double labeled for p-c-Jun (Ser63) in red
(TRITC) and HER2/neu in green (FITC) and counterstained with DAPI (blue) to define the nuclei. B. Flow cytometric analysis
of control (left) and Iressa-treated (right) MAM-1 cultures. Cells were dual labeled for p-c-Jun (Ser63) and α-SMA. Density
plots compare p-c-Jun (Ser63) expression levels in the α-SMA negative and positive subpopulations in control and Iressatreated MAM-1 cultures. Mean Channel fluorescent values for p-c-Jun (Ser63) are indicated in the respective quadrants. Histogram analyses for p-c-Jun (Ser63) expression in the α-SMA negative subpopulations were generated from dot plots of p-Jun
(Ser63)-PE versus Forward Scatter and gating on the respective the S (small) and L (large) fractions. Histograms of these tumor
cell subpopulations demonstrate different baseline levels (Left) of p-c-Jun (Ser63) levels and Iressa responsiveness (Right) in
small (S) and large (L) cells. Mean channel fluorescent values for p-c-Jun (Ser63) levels are indicated above the peaks. Parallel
samples were dual stained for HER2/neu and p-c-Jun (Ser63) to verify these data (not shown).
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Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line
Expression Relative to Universal Mouse RNAa
Agilent Accession Genbank Accession
MAM
Bam1a
Genes present in the tumor-specific HER-2/neu-Induced Gene Expression Signature described by Astolfi
A_51_P184886

NM_011920

5.27

19.10

A_52_P336142

NM_011920

4.90

17.77

A_51_P342567

NM_031185

9.10

6.60

A_51_P445166

NM_019959

11.89

17.02

A_51_P455647
A_51_P303160
A_52_P159232

NM_009801
NM_007482
NM_011926

7.56
14.32
20.60

9.21
23.23
24.52

A_51_P183446

NM_001039185

10.69

12.16

A_51_P171728

NM_011926

9.77

12.34

A_52_P240706

NM_007543

23.70

31.29

A_51_P362066
A_51_P495049

NM_007695
NM_009897

8.34
10.34

3.89
11.46

A_51_P343309

NM_009908

5.83

10.54

A_52_P197963

NM_009936

7.33

10.23

A_52_P507877

NM_007729

41.31

30.23

A_51_P459477

NM_007729

34.68

28.45

A_51_P227280
A_51_P227275
A_52_P51078
A_51_P275976
A_52_P366842
A_51_P158037
A_52_P157158
A_52_P252931
A_51_P502614

NM_007786
NM_007786
NM_007801
NM_010070
NM_010070
NM_013505
NM_013505
NM_013505
NM_026268

53.04
26.87
23.49

56.89
32.53
35.47
3.24
4.94
12.52
46.62
265.33
6.46

A_51_P455866
A_51_P307979
A_51_P246166

NM_010125
NM_007960
NM_007969

27.80
10.06

29.60
2.46
10.23

A_52_P329207

NM_007969

13.14

12.84

A_51_P329394
A_52_P377791

NM_008034
NM_008557

6.64
30.34

8.48
40.63

A_51_P282538

NM_008077

28.43

73.47

A_52_P144310

NM_008077

27.33

68.46

A_51_P486810

NM_030677

13.90

14.97

A_51_P258409

NM_010423

13.98

30.78

A_51_P365152

NM_010474

23.53

48.48

A_52_P281702

NM_010518

2.12

3.08

A_51_P204153

NM_010518

4.25

10.70

A_51_P510156
A_52_P153864
A_51_P394190
A_52_P415168

NM_008491
NM_010723
NM_010723
NM_019394

9.56
2.77
3.05
8.35

10.11
3.75
4.24
8.26

A_52_P415167

NM_019394

18.65

22.26

A_52_P174346

NM_019394

7.84

8.15

2.49
11.59
42.42
107.26
4.28

Gene Description and Symbol

Mus musculus ATP-binding cassette, sub-family G (WHITE), member
2 (Abcg2), mRNA [NM_011920]
Mus musculus ATP-binding cassette, sub-family G (WHITE), member
2 (Abcg2), mRNA [NM_011920]
Mus musculus A kinase (PRKA) anchor protein (gravin) 12 (Akap12),
mRNA [NM_031185]
Mus musculus C1q and tumor necrosis factor related protein 1
(C1qtnf1), mRNA [NM_019959]
Mus musculus carbonic anhydrase 2 (Car2), mRNA [NM_009801]
Mus musculus arginase 1, liver (Arg1), mRNA [NM_007482]
Mus musculus CEA-related cell adhesion molecule 1 (Ceacam1),
mRNA [NM_011926]
Mus musculus CEA-related cell adhesion molecule 1, mRNA (cDNA
clone MGC:18556 IMAGE:4218391), complete cds [BC016891]
Mus musculus CEA-related cell adhesion molecule 1 (Ceacam1),
mRNA [NM_011926]
Mus musculus CEA-related cell adhesion molecule 2 (Ceacam2),
mRNA [NM_007543]
Mus musculus chitinase 3-like 1 (Chi3l1), mRNA [NM_007695]
Mus musculus creatine kinase, mitochondrial 1, ubiquitous (Ckmt1),
mRNA [NM_009897]
Mus musculus cytidine monophospho-N-acetylneuraminic acid
synthetase (Cmas), mRNA [NM_009908]
Mus musculus procollagen, type IX, alpha 3 (Col9a3), mRNA
[NM_009936]
Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA
[NM_007729]
Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA
[NM_007729]
Mus musculus casein kappa (Csnk), mRNA [NM_007786]
Mus musculus casein kappa (Csnk), mRNA [NM_007786]
Mus musculus cathepsin H (Ctsh), mRNA [NM_007801]
Mus musculus docking protein 1 (Dok1), mRNA [NM_010070]
Mus musculus docking protein 1 (Dok1), mRNA [NM_010070]
Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
Mus musculus desmocollin 2 (Dsc2), mRNA [NM_013505]
Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA
[NM_026268]
Mus musculus E74-like factor 5 (Elf5), mRNA [NM_010125]
Mus musculus ets variant gene 1 (Etv1), mRNA [NM_007960]
Mus musculus extracellular proteinase inhibitor (Expi), mRNA
[NM_007969]
Mus musculus extracellular proteinase inhibitor (Expi), mRNA
[NM_007969]
Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
Mus musculus FXYD domain-containing ion transport regulator 3
(Fxyd3), mRNA [NM_008557]
Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA
[NM_008077]
Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA
[NM_008077]
Mus musculus glutathione peroxidase 2 (Gpx2), mRNA
[NM_030677]
Mus musculus hairy/enhancer-of-split related with YRPW motif 1
(Hey1), mRNA [NM_010423]
Mus musculus heparan sulfate (glucosamine) 3-O-sulfotransferase 1
(Hs3st1), mRNA [NM_010474]
Mus musculus insulin-like growth factor binding protein 5 (Igfbp5),
mRNA [NM_010518]
Mus musculus insulin-like growth factor binding protein 5 (Igfbp5),
mRNA [NM_010518]
Mus musculus lipocalin 2 (Lcn2), mRNA [NM_008491]
Mus musculus LIM domain only 4 (Lmo4), mRNA [NM_010723]
Mus musculus LIM domain only 4 (Lmo4), mRNA [NM_010723]
Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA
[NM_019394]
Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA
[NM_019394]
Mus musculus melanoma inhibitory activity 1 (Mia1), mRNA
[NM_019394]
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Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line (Continued)
A_51_P220062

NM_008609

10.60

15.42

A_51_P139780

NM_009402

6.81

7.64

A_51_P195958

NM_009344

3.26

6.05

A_52_P418791

NM_011254

15.11

16.38

A_51_P423484

NM_011254

8.26

7.45

A_52_P197215

NM_028777

2.76

4.29

A_52_P197223

NM_028777

3.32

5.72

A_51_P268094

NM_009255

22.21

38.32

A_52_P637988

NM_009199

40.88

62.00

A_51_P110759

NM_009199

20.06

26.16

A_52_P426605

NM_021301

23.10

30.57

A_51_P107362

NM_007706

13.23

14.79

A_51_P346704

XM_128139

10.67

11.19

A_52_P192625

XM_128139

23.80

36.33

A_52_P161630

NM_145933

A_51_P101375

NM_145933

2.35

5.29

A_51_P183940

NM_016866

2.21

3.02

A_52_P447944

NM_008532

5.04

8.96

A_51_P418820

NM_009335

40.16

37.90

A_51_P338262
A_51_P482503

NM_011619
NM_009413

5.37
21.46

8.17
34.02

A_51_P506822

NM_011674

42.90

81.82

A_52_P439263

NM_011674

56.91

70.50

4.23

Mus musculus matrix metalloproteinase 15 (Mmp15), mRNA
[NM_008609]
Mus musculus peptidoglycan recognition protein 1 (Pglyrp1), mRNA
[NM_009402]
Mus musculus pleckstrin homology-like domain, family A, member 1
(Phlda1), mRNA [NM_009344]
Mus musculus retinol binding protein 1, cellular (Rbp1), mRNA
[NM_011254]
Mus musculus retinol binding protein 1, cellular (Rbp1), mRNA
[NM_011254]
Mus musculus SEC14-like 1 (S. cerevisiae) (Sec14l1), mRNA
[NM_028777]
Mus musculus SEC14-like 1 (S. cerevisiae) (Sec14l1), mRNA
[NM_028777]
Mus musculus serine (or cysteine) proteinase inhibitor, clade E,
member 2 (Serpine2), mRNA [NM_009255]
Mus musculus solute carrier family 1 (neuronal/epithelial high affinity
glutamate transporter, system Xag), member 1 (Slc1a1), mRNA
[NM_009199]
Mus musculus solute carrier family 1 (neuronal/epithelial high affinity
glutamate transporter, system Xag), member 1 (Slc1a1), mRNA
[NM_009199]
Mus musculus solute carrier family 15 (H+/peptide transporter),
member 2 (Slc15a2), mRNA [NM_021301]
Mus musculus suppressor of cytokine signaling 2 (Socs2), mRNA
[NM_007706]
Mus musculus SRY-box containing gene 10, mRNA (cDNA clone
MGC:32314 IMAGE:5027211), complete cds. [BC023356]
Mus musculus SRY-box containing gene 10, mRNA (cDNA clone
MGC:32314 IMAGE:5027211), complete cds. [BC023356]
Mus musculus beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1),
mRNA [NM_145933]
Mus musculus beta galactoside alpha 2,6 sialyltransferase 1 (St6gal1),
mRNA [NM_145933]
Mus musculus serine/threonine kinase 39, STE20/SPS1 homolog
(yeast) (Stk39), mRNA [NM_016866]
Mus musculus tumor-associated calcium signal transducer 1
(Tacstd1), mRNA [NM_008532]
Mus musculus transcription factor AP-2, gamma (Tcfap2c), mRNA
[NM_009335]
Mus musculus troponin T2, cardiac (Tnnt2), mRNA [NM_011619]
Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA
[NM_009413]
Mus musculus UDP galactosyltransferase 8A (Ugt8a), mRNA
[NM_011674]
Mus musculus UDP galactosyltransferase 8A (Ugt8a), mRNA
[NM_011674]

Genes expressed in common with the mouse orthologs of the human "intrinsic" gene list of published by Sorlie
A_51_P311038

NM_001024139

7.11

9.21

A_51_P366811
A_51_P163015

NM_007470
NM_172309

45.17
2.77

36.20
14.02

A_51_P455647
A_51_P302823

NM_009801
NM_019686

7.57
4.02

9.21
11.39

A_51_P165185
A_52_P507877

NM_016887
NM_007729

11.54
41.32

15.50
30.23

A_51_P459477

NM_007729

34.69

28.45

A_51_P502614

NM_026268

4.28

6.46

A_51_P116940

NM_007940

15.92

5.95

A_51_P455932

NM_007974

12.81

33.87

A_52_P192418

NM_010175

2.63

4.90

A_51_P382925

NM_010175

2.16

3.61

A_52_P100252

NM_007988

3.23

3.40

A_52_P136162

NM_010206

2.27

4.37

Mus musculus a disintegrin-like and metalloprotease (reprolysin type)
with thrombospondin type 1 motif, 15 (Adamts15), mRNA
[NM_001024139]
Mus musculus apolipoprotein D (Apod), mRNA [NM_007470]
Mus musculus aryl hydrocarbon receptor nuclear translocator-like 2
(Arntl2), mRNA [NM_172309]
Mus musculus carbonic anhydrase 2 (Car2), mRNA [NM_009801]
Mus musculus calcium and integrin binding family member 2 (Cib2),
mRNA [NM_019686]
Mus musculus claudin 7 (Cldn7), mRNA [NM_016887]
Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA
[NM_007729]
Mus musculus procollagen, type XI, alpha 1 (Col11a1), mRNA
[NM_007729]
Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA
[NM_026268]
Mus musculus epoxide hydrolase 2, cytoplasmic (Ephx2), mRNA
[NM_007940]
Mus musculus coagulation factor II (thrombin) receptor-like 1 (F2rl1),
mRNA [NM_007974]
Mus musculus Fas (TNFRSF6)-associated via death domain (Fadd),
mRNA [NM_010175]
Mus musculus Fas (TNFRSF6)-associated via death domain (Fadd),
mRNA [NM_010175]
Mus musculus clone:A630082H08 product:fatty acid synthase, full
insert sequence. [AK080374]
Mus musculus fibroblast growth factor receptor 1 (Fgfr1), mRNA
[NM_010206]
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Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line (Continued)
A_52_P668810

NM_010206

3.81

A_51_P335000

NM_010211

5.05

A_51_P329394
A_52_P217710

NM_008034
NM_008056

6.64

8.48
3.08

A_51_P282538

NM_008077

28.43

73.47

A_52_P144310

NM_008077

27.33

68.46

A_51_P380005

NM_015736

32.95

69.29

A_51_P379997

NM_015736

38.50

82.09

A_51_P462422

NM_008124

A_52_P16419

NM_010271

A_52_P415996

NM_008184

A_51_P179664

NM_008185

3.67

6.80

A_52_P281702

NM_010518

2.12

3.08

A_51_P204153

NM_010518

4.25

10.70

A_52_P401386
A_52_P642488

NM_010593
NM_008430

3.74
24.28

5.28
26.37

A_51_P307964

NM_010662

3.11

6.39

A_51_P324814

NM_010664

2.93

3.89

A_52_P410685

NM_033073

12.42

14.59

A_51_P242400

NM_031170

2.56

3.75

A_51_P174943
A_51_P220062

NM_008485
NM_008609

6.90
10.60

10.66
15.42

A_51_P514085

NM_013606

3.75

6.35

A_52_P608097
A_51_P486150
A_52_P458279
A_51_P248345

NM_008756
NM_008756
NM_011169
NM_009334

17.70
10.05
15.09

41.15
12.72
21.23
17.92

A_51_P418820

NM_009335

40.16

37.90

A_51_P240614

NM_008536

3.79

5.43

A_51_P482503

NM_009413

21.46

34.02

A_51_P106059

NM_009423

2.81

3.48

A_52_P78403

NM_009423

2.90

5.78

5.07
2.43

6.66
6.29

Mus musculus fibroblast growth factor receptor 1 (Fgfr1), mRNA
[NM_010206]
Mus musculus four and a half LIM domains 1 (Fhl1), mRNA
[NM_010211]
Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
Mus musculus frizzled homolog 6 (Drosophila) (Fzd6), mRNA
[NM_008056]
Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA
[NM_008077]
Mus musculus glutamic acid decarboxylase 1 (Gad1), mRNA
[NM_008077]
Mus musculus UDP-N-acetyl-alpha-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 3 (Galnt3), mRNA [NM_015736]
Mus musculus UDP-N-acetyl-alpha-D-galactosamine:polypeptide Nacetylgalactosaminyltransferase 3 (Galnt3), mRNA [NM_015736]
Mus musculus gap junction membrane channel protein beta 1 (Gjb1),
mRNA [NM_008124]
Mus musculus glycerol-3-phosphate dehydrogenase 1 (soluble)
(Gpd1), mRNA [NM_010271]
Mus musculus glutathione S-transferase, mu 6 (Gstm6), mRNA
[NM_008184]
Mus musculus glutathione S-transferase, theta 1 (Gstt1), mRNA
[NM_008185]
Mus musculus insulin-like growth factor binding protein 5 (Igfbp5),
mRNA [NM_010518]
Mus musculus insulin-like growth factor binding protein 5 (Igfbp5),
mRNA [NM_010518]
Mus musculus junction plakoglobin (Jup), mRNA [NM_010593]
Mus musculus potassium channel, subfamily K, member 1 (Kcnk1),
mRNA [NM_008430]
Mus musculus keratin complex 1, acidic, gene 13 (Krt1-13), mRNA
[NM_010662]
Mus musculus keratin complex 1, acidic, gene 18 (Krt1-18), mRNA
[NM_010664]
Mus musculus keratin complex 2, basic, gene 7 (Krt2-7), mRNA
[NM_033073]
Mus musculus keratin complex 2, basic, gene 8 (Krt2-8), mRNA
[NM_031170]
Mus musculus laminin, gamma 2 (Lamc2), mRNA [NM_008485]
Mus musculus matrix metalloproteinase 15 (Mmp15), mRNA
[NM_008609]
Mus musculus myxovirus (influenza virus) resistance 2 (Mx2), mRNA
[NM_013606]
Mus musculus occludin (Ocln), mRNA [NM_008756]
Mus musculus occludin (Ocln), mRNA [NM_008756]
Mus musculus prolactin receptor (Prlr), mRNA [NM_011169]
Mus musculus transcription factor AP-2 beta (Tcfap2b), transcript
variant 1, mRNA [NM_009334]
Mus musculus transcription factor AP-2, gamma (Tcfap2c), mRNA
[NM_009335]
Mus musculus transmembrane 4 superfamily member 1 (Tm4sf1),
mRNA [NM_008536]
Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA
[NM_009413]
Mus musculus Tnf receptor associated factor 4 (Traf4), mRNA
[NM_009423]
Mus musculus Tnf receptor associated factor 4 (Traf4), mRNA
[NM_009423]

Genes expressed in common with the MMTV/neu mammary tumor gene signature described by Landis
A_51_P320852
A_51_P242265

NM_007657
NM_009950

2.52
2.45

7.50
4.36

A_52_P559779
A_51_P249848
A_52_P88091
A_52_P601757

NM_007883
NM_007883
NM_007883
NM_007883

17.30
11.40
22.00
76.45

22.26
13.77
38.20
101.83

A_51_P502614

NM_026268

4.28

6.46

A_51_P246166

NM_007969

10.06

10.23

A_52_P329207

NM_007969

13.14

12.84

A_51_P329394
A_51_P352303

NM_008034
NM_011983

6.64
5.94

8.48
8.58

Mus musculus CD9 antigen (Cd9), mRNA [NM_007657]
Mus musculus CASP2 and RIPK1 domain containing adaptor with
death domain (Cradd), mRNA [NM_009950]
Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
Mus musculus desmoglein 2 (Dsg2), mRNA [NM_007883]
Mus musculus desmoglein 2, mRNA (cDNA clone IMAGE:4036406),
partial cds [BC034056]
Mus musculus dual specificity phosphatase 6 (Dusp6), mRNA
[NM_026268]
Mus musculus extracellular proteinase inhibitor (Expi), mRNA
[NM_007969]
Mus musculus extracellular proteinase inhibitor (Expi), mRNA
[NM_007969]
Mus musculus folate receptor 1 (adult) (Folr1), mRNA [NM_008034]
Mus musculus homer homolog 2 (Drosophila) (Homer2), mRNA
[NM_011983]
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Table 1: Expression of HER2/neu ErbB-2 Breast Cancer Signature genes in MAM-1 Co-cultures and the Bam1a cell line (Continued)
A_52_P176573

NM_011983

7.52

12.27

A_51_P510156
A_52_P382785
A_51_P289889
A_52_P17556

NM_008491
NM_033525
NM_033525
NM_134249

9.56
3.71
3.57
6.84

10.11
12.17
9.38
18.37

A_51_P500906

NM_134249

12.27

24.24

A_51_P482503

NM_009413

21.46

34.02

Mus musculus homer homolog 2 (Drosophila) (Homer2), mRNA
[NM_011983]
Mus musculus lipocalin 2 (Lcn2), mRNA [NM_008491]
Mus musculus nephronectin (Npnt), mRNA [NM_033525]
Mus musculus nephronectin (Npnt), mRNA [NM_033525]
Mus musculus T-cell immunoglobulin and mucin domain containing 2
(Timd2), mRNA [NM_134249]
Mus musculus T-cell immunoglobulin and mucin domain containing 2
(Timd2), mRNA [NM_134249]
Mus musculus tumor protein D52-like 1 (Tpd52l1), mRNA
[NM_009413]

Expression of genes associated with the human HER2/neu chromosome 17q amplicon by Bertucci
A_51_P317176

NM_009971

12.40

13.05

A_51_P216179

NM_010152

4.71

8.69

A_51_P230382

NM_008815

2.63

3.66

A_51_P368823

NM_010346

3.09

4.64

A_52_P401386
A_52_P567306
A_51_P182462
A_51_P387123

NM_010593
NM_010688
NM_010688
NM_011854

3.74
2.95
2.46
2.77

5.28
4.98
3.44
4.06

Mus musculus colony stimulating factor 3 (granulocyte) (Csf3),
mRNA [NM_009971]
Mus musculus v-erb-b2 erythroblastic leukemia viral oncogene
homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
(Erbb2), transcript variant 2, mRNA [NM_010152]
Mus musculus ets variant gene 4 (E1A enhancer binding protein,
E1AF) (Etv4), mRNA [NM_008815]
Mus musculus growth factor receptor bound protein 7 (Grb7),
mRNA [NM_010346]
Mus musculus junction plakoglobin (Jup), mRNA [NM_010593]
Mus musculus LIM and SH3 protein 1 (Lasp1), mRNA [NM_010688]
Mus musculus LIM and SH3 protein 1 (Lasp1), mRNA [NM_010688]
Mus musculus 2'-5' oligoadenylate synthetase-like 2 (Oasl2), mRNA
[NM_011854]

aAverage

fold difference is the ratio (n = 3, p value cutoff > .05) MAM-1 or Bam1a RNA to Universal Mouse RNA. RNA from MAM-1 or Bam1a was
labeled in red color (cy5), universal RNA is labeled in green (cy3). Three independent RNA preparations per condition were analyzed on three
separate chips and averaged; a confidence cutoff of >0.95 was used for the raw values of red/green before normalization. The fold change (**MAM1 or Bam1a/**Universal Mouse) = Normalized ratio value(cy5/cy3). The MAM-1 and Bam1a transcriptomes include genes that are differentially
increased relative to the Universal mouse RNA by at least 2-fold.

fibroblasts (but not normal skin fibroblasts) was required
for myofibroblast differentiation (i.e., expression of
alpha-SMA) and resembled the advanced stages of desmoplastic carcinomas [11], similar to what we observe in the
homotypic MAM-1 co-culture model. In these studies,
expression of PMP22 was identified as a candidate gene in
modulating tumor cell interactions with fibroblast. In
MAM-1, PMP22 is upregulated approximately 15-fold and
thus, may also play a role in the MAM-1 model.
Effect of Iressa on signal transduction in MAM-1
Western blot and microarray analyses revealed differential
expression of the HER2/neu and EGFR in the respective
tumor and stroma fractions of MAM-1 co-cultures. HER2/
neu was exclusively expressed in the mammary tumor cell
fraction and EGFR was approximately 8-fold higher in the
stromal cell population. In so much as the EGFR is
approximately 50-fold more sensitive to Iressa
(IC50>0.080 µM) compared to the c-erbB-2 tyrosine
kinase (IC50~3 µM) in vitro, we anticipated that EGFR in
the stromal cell population was a likely target for the
inhibitory activities of Iressa. Indeed, it has been suggested that targeting tumor associated fibroblasts [30] and
the stromal EGFR may be a viable approach for preventing
tumor progression and impeding the angiogenic switch. It
has been shown that Iressa can differentially modulate
fibrosis in various models of injury and disease [31-33]. It

is important to distinguish, that in most injury models,
the fibroblasts that are targeted as effectors of fibrosis are
normal stromal fibroblasts and not phenotypically similar to the cancer associated fibroblasts/myofibroblasts
that represent the stromal cells in the MAM-1 model. We
expected that the response to Iressa in the MAM-1 stromal
cells could be effected by their intrinsic sensitivity to Iressa
and the microenvironment. Thus, we used the MAM-1 coculture model to determine the selectivity and specificity
of Iressa for the HER2/neu over-expressing mammary
tumor cells versus the EGFR-expressing stromal cells by
evaluating signal transduction downstream of these RTKs.
In MAM-1 co-cultures that are stimulated by replacing the
culture medium, strong cytoplasmic expression of phosphorylated p44/42 MAPK is readily observed (Fig. 5A).
Inclusion of 1 µM Iressa eliminates this response. By flow
cytometric analysis we determined the dose-response for
p44/42 MAPK and pMEK1/2 in the ErbB-2+ (tumor cell)
and ErbB-2-(stromal cell) subpopulations in MAM-1 cocultures. We observed a dose-dependent decrease in
pp44/42 MAPK and pMEK1/2 phosphorylation in tumor
cells with maximal decreases of 90% and 40%, respective
(Fig. 5B). We also observed a modest (38%) decrease in
stromal cell phospho-pp44/42 MAPK at all doses of Iressa
but no effect of pMEK1/2 phosphorylation, suggesting a
small inhibitory effect of Iressa on the EGFR in the stroma.
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Table 2: Differentially expressed Fibromatosis and Desmoplastic response genes in the MAM-1 Transcriptome
Agilent Accession

Genbank Accession

Ratio of MAM-1
vs. Bam1a

p-value (n = 3)

A_51_P162272

NM_009524

5.95

2.58E-03

A_51_P390804

NM_016873

125.00

8.89E-06

A_51_P220343

NM_018865

16.66

4.06E-06

A_52_P658611

NM_007742

19.92

4.09E-03

A_52_P525107

NM_007742

187.97

1.12E-05

A_51_P377094

NM_007742

37.17

9.02E-08

A_51_P414637

NM_015734

168.63

7.15E-06

A_52_P684242

NM_009930

4.93

7.45E-05

A_51_P515605

NM_009930

94.34

1.67E-09

A_51_P474496

NM_009933

12.21

6.30E-08

A_51_P502132

NM_011985

7.69

1.96E-07

A_51_P269166

NM_021412

13.33

1.11E-02

A_51_P293087

NM_008606

4.76

7.12E-06

A_51_P404077

NM_020510

3.45

3.09E-06

A_52_P597634

NM_021457

4.55

5.25E-07

A_52_P224801

NM_007993

130.03

1.47E-03

A_51_P467224

NM_007993

240.38

8.77E-05

A_52_P220176

NM_015814

20.88

3.70E-02

A_52_P489295

NM_009621

4.22

2.72E-05

A_52_P213932

NM_009621

3.10

1.94E-05

A_52_P280044

NM_009616

16.21

1.63E-05

A_51_P267447

NM_009616

10.35

8.95E-04

A_52_P290457

NM_007400

33.11

4.05E-03

A_51_P510882

NM_007400

9.35

1.38E-03

A_51_P350817

NM_009922

38.46

1.29E-04

A_52_P599578

NM_145575

1.24

1.03E-02

A_51_P357573

NM_145575

1.25

3.07E-02

A_51_P157042

NM_010217

14.33

1.71E-04

A_51_P124748

NM_009368

0.45

7.08E-04

A_51_P212754

NM_009369

11.76

1.54E-03

A_51_P472292

NM_008048

65.79

6.80E-09

A_51_P110301

NM_009778

4.59

3.95E-05

A_51_P218774

NM_026418

2.74

9.21E-04

A_51_P224843

NM_021278

2.84

2.24E-03

Gene Description and Symbol

Reference

Mus musculus wingless-related MMTV integration
site 5A (Wnt5a), mRNA [NM_009524]
Mus musculus WNT1 inducible signaling pathway
protein 2 (Wisp2), mRNA [NM_016873]
Mus musculus WNT1 inducible signaling pathway
protein 1 (Wisp1), mRNA [NM_018865]
Mus musculus procollagen, type I, alpha 1
(Col1a1), mRNA [NM_007742]
Mus musculus procollagen, type I, alpha 1
(Col1a1), mRNA [NM_007742]
Mus musculus procollagen, type I, alpha 1
(Col1a1), mRNA [NM_007742]
Mus musculus procollagen, type V, alpha 1
(Col5a1), mRNA [NM_015734]
Mus musculus procollagen, type III, alpha 1
(Col3a1), mRNA [NM_009930]
Mus musculus procollagen, type III, alpha 1
(Col3a1), mRNA [NM_009930]
Mus musculus procollagen, type VI, alpha 1
(Col6a1), mRNA [NM_009933]
Mus musculus matrix metalloproteinase 23
(Mmp23), mRNA [NM_011985]
Mus musculus matrix metalloproteinase 19
(Mmp19), mRNA [NM_021412]
Mus musculus matrix metalloproteinase 11
(Mmp11), mRNA [NM_008606]
Mus musculus frizzled homolog 2 (Drosophila)
(Fzd2), mRNA [NM_020510]
Mus musculus frizzled homolog 1 (Drosophila)
(Fzd1), mRNA [NM_021457]
Mus musculus fibrillin 1 (Fbn1), mRNA
[NM_007993]
Mus musculus fibrillin 1 (Fbn1), mRNA
[NM_007993]
Mus musculus dickkopf homolog 3 (Xenopus
laevis) (Dkk3), mRNA [NM_015814]
Mus musculus a disintegrin-like and
metalloprotease (reprolysin type) with
thrombospondin type 1 motif, 1 (Adamts1),
mRNA [NM_009621]
Mus musculus a disintegrin-like and
metalloprotease (reprolysin type) with
thrombospondin type 1 motif, 1 (Adamts1),
mRNA [NM_009621]
Mus musculus a disintegrin and metalloproteinase
domain 19 (meltrin beta) (Adam19), mRNA
[NM_009616]
Mus musculus a disintegrin and metalloproteinase
domain 19 (meltrin beta) (Adam19), mRNA
[NM_009616]
Mus musculus a disintegrin and metalloproteinase
domain 12 (meltrin alpha) (Adam12), mRNA
[NM_007400]
Mus musculus a disintegrin and metalloproteinase
domain 12 (meltrin alpha) (Adam12), mRNA
[NM_007400]
Mus musculus calponin 1 (Cnn1), mRNA
[NM_009922]
Mus musculus caldesmon 1 (Cald1), mRNA
[NM_145575]
Mus musculus caldesmon 1 (Cald1), mRNA
[NM_145575]
Mus musculus connective tissue growth factor
(Ctgf), mRNA [NM_010217]
Mus musculus transforming growth factor, beta 3
(Tgfb3), mRNA [NM_009368]
Mus musculus transforming growth factor, beta
induced (Tgfbi), mRNA [NM_009369]
Mus musculus insulin-like growth factor binding
protein 7 (Igfbp7), mRNA [NM_008048]
Mus musculus complement component 3 (C3),
mRNA [NM_009778]
Mus musculus regulator of G-protein signalling 10
(Rgs10), mRNA [NM_026418]
Mus musculus thymosin, beta 4, X chromosome
(Tmsb4x), mRNA [NM_021278]

West
West
West
West, Iacobuzio-Donahue
West, Iacobuzio-Donahue
West, Iacobuzio-Donahue
West
West
West
West
West
West
West
West
West
West
West
West
West

West

West
West
West, Peduto
West, Peduto
West
West
West
West
West
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
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Table 2: Differentially expressed Fibromatosis and Desmoplastic response genes in the MAM-1 Transcriptome (Continued)
A_51_P111210

NM_133786

1.10

1.45E-01

A_52_P101852

NM_009242

27.25

1.90E-07

A_51_P431087

NM_009242

67.11

1.96E-08

A_51_P452876

NM_021515

7.46

3.48E-06

A_51_P149562

NM_009686

6.13

1.52E-04

A_52_P49250

NM_010152

0.86

4.40E-03

A_51_P216179

NM_010152

0.54

3.14E-03

A_51_P341736

NM_008610

2.74

1.93E-04

A_51_P258529

NM_008885

15.77

3.73E-05

A_51_P213359

NM_008216

23.70

1.46E-07

A_52_P582374

NM_178825

0.04

5.59E-03

A_51_P376050

NM_029495

0.03

2.78E-03

A_51_P127681

NM_013885

3.62

1.28E-07

A_51_P392687

NM_011701

25.000

5.47E-04

A_52_P56471

NM_007912

4.35

8.57E-06

A_51_P392242

NM_007912

4.17

1.10E-05

A_52_P674338

NM_207655

7.14

1.90E-03

A_52_P106259

NM_207655

11.56

2.06E-05

A_51_P414813

NM_010153

0.61

3.13E-03

A_51_P342050

NM_010153

0.58

3.28E-02

A_52_P420504

NM_007392

17.18

7.97E-05

A_52_P210078

NM_007392

101.94

6.74E-05

A_51_P103396

NM_016879

0.260

2.69E-04

A_51_P356642

NM_008471

5.550

7.53E-06

A_51_P482128

NM_008469

2.760

3.01E-04

A_51_P118225

NM_028078

0.028

7.55E-04

A_51_P358354

NM_023277

30.030

2.21E-06

A_52_P374846

NM_023844

19.120

9.97E-04

A_51_P418375

NM_023844

10.256

8.90E-04

A_52_P93974

NM_021359

0.316

1.46E-02

A_52_P459521

NM_001005607

0.261

3.06E-05

A_51_P382970

NM_133721

25.125

3.19E-02

A_52_P413034

NM_008398

2.985

2.73E-02

A_51_P181671

NM_008398

3.401

4.71E-03

A_52_P364140

NM_010577

30.030

1.76E-06

A_52_P223495

NM_010576

0.304

4.71E-02

Mus musculus SMC4 structural maintenance of
chromosomes 4-like 1 (yeast) (Smc4l1), mRNA
[NM_133786]
Mus musculus secreted acidic cysteine rich
glycoprotein (Sparc), mRNA [NM_009242]
Mus musculus secreted acidic cysteine rich
glycoprotein (Sparc), mRNA [NM_009242]
Mus musculus adenylate kinase 1 (Ak1), mRNA
[NM_021515]
Mus musculus amyloid beta (A4) precursor
protein-binding, family B, member 2 (Apbb2),
mRNA [NM_009686]
Mus musculus v-erb-b2 erythroblastic leukemia
viral oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog (avian) (Erbb2),
transcript variant 2, mRNA [NM_010152]
Mus musculus v-erb-b2 erythroblastic leukemia
viral oncogene homolog 2, neuro/glioblastoma
derived oncogene homolog (avian) (Erbb2),
transcript variant 2, mRNA [NM_010152]
Mus musculus matrix metalloproteinase 2
(Mmp2), mRNA [NM_008610]
Mus musculus peripheral myelin protein (Pmp22),
mRNA [NM_008885]
Mus musculus hyaluronan synthase 2 (Has2),
mRNA [NM_008216]
Mus musculus epithelial stromal interaction 1
(breast) (Epsti1), transcript variant b, mRNA
[NM_178825]
Mus musculus epithelial stromal interaction 1
(breast) (Epsti1), transcript variant a, mRNA
[NM_029495]
Mus musculus chloride intracellular channel 4
(mitochondrial) (Clic4), mRNA [NM_013885]
Mus musculus vimentin (Vim), mRNA
[NM_011701]
Mus musculus epidermal growth factor receptor
(Egfr), transcript variant 2, mRNA [NM_007912]
Mus musculus epidermal growth factor receptor
(Egfr), transcript variant 2, mRNA [NM_007912]
Mus musculus epidermal growth factor receptor
(Egfr), transcript variant 1, mRNA [NM_207655]
Mus musculus epidermal growth factor receptor
(Egfr), transcript variant 1, mRNA [NM_207655]
Mus musculus v-erb-b2 erythroblastic leukemia
viral oncogene homolog 3 (avian) (Erbb3), mRNA
[NM_010153]
Mus musculus v-erb-b2 erythroblastic leukemia
viral oncogene homolog 3 (avian) (Erbb3), mRNA
[NM_010153]
Mus musculus actin, alpha 2, smooth muscle,
aorta (Acta2), mRNA [NM_007392]
Mus musculus actin, alpha 2, smooth muscle,
aorta (Acta2), mRNA [NM_007392]
Mus musculus keratin complex 2, basic, gene 18
(Krt2-18), mRNA [NM_016879]
Mus musculus keratin complex 1, acidic, gene 19
(Krt1-19), mRNA [NM_008471]
Mus musculus keratin complex 1, acidic, gene 15
(Krt1-15), mRNA [NM_008469]
Mus musculus junction adhesion molecule 4
(Jam4), mRNA [NM_028078]
Mus musculus junction adhesion molecule 3
(Jam3), mRNA [NM_023277]
Mus musculus junction adhesion molecule 2
(Jam2), mRNA [NM_023844]
Mus musculus junction adhesion molecule 2
(Jam2), mRNA [NM_023844]
Mus musculus integrin beta 6 (Itgb6), mRNA
[NM_021359]
Mus musculus integrin beta 4 (Itgb4), transcript
variant 3, mRNA [NM_001005607]
Mus musculus integrin alpha 9 (Itga9), mRNA
[NM_133721]
Mus musculus integrin alpha 7 (Itga7), mRNA
[NM_008398]
Mus musculus integrin alpha 7 (Itga7), mRNA
[NM_008398]
Mus musculus integrin alpha 5 (fibronectin
receptor alpha) (Itga5), mRNA [NM_010577]
Mus musculus integrin alpha 4 (Itga4), mRNA
[NM_010576]

Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue
Iacobuzio-Donahue

Iacobuzio-Donahue

Wang, Singer
Kunz-Schughart
Li
Gudjonsson
Gudjonsson
Suh, Ronnov-Jessen
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Table 2: Differentially expressed Fibromatosis and Desmoplastic response genes in the MAM-1 Transcriptome (Continued)
A_51_P515056

NM_013565

0.316

9.78E-05

A_51_P230405

NM_013565

0.260

5.62E-05

A_52_P612019

NM_008396

3.300

3.55E-02

Mus musculus integrin alpha 3 (Itga3), mRNA
[NM_013565]
Mus musculus integrin alpha 3 (Itga3), mRNA
[NM_013565]
Mus musculus integrin alpha 2 (Itga2), mRNA
[NM_008396]

aAverage

fold difference is the ratio (n = 3, p value cutoff > .05) compares the expression levels of MAM-1 RNA normalized to Universal Mouse
RNA to Bam1a RNA normalized to Universal Mouse RNA. RNA from MAM-1 or Bam1a was labeled in red color (cy5), universal RNA is labeled in
green (cy3). Three independent RNA preparations per condition were analyzed on three separate chips and averaged; a confidence cutoff of >0.95
was used for the raw values of red/green before normalization. The fold change (**MAM-1 or Bam1a/**Universal Mouse) = Normalized ratio
value(cy5/cy3). P-values are for the comparisons between the MAM-1 and Bam1a. The references associated with specific genes are indicated in the
text of the manuscript.

To determine the long term impact of these effects on cell
growth and survival we treated MAM-1 co-cultures with
Iressa for longer periods of time.
Treatment of MAM-1 with Iressa generates a fibrotic
response in vitro
When treated for an extended period of time with Iressa,
the morphology of the MAM-1 co-culture recapitulated a
fibrotic response such that tumor cell nests and islands
gradually eroded away and stromal cells increased in density forming multi-cell layer nests (Fig. 6A). Our primary
observation was that the morphology and cellularity of
the co-cultures was dramatically altered. Within 24 h of
treatment with 1 µM Iressa, there was a decrease in the cellularity of tumor cell nests and an increase in the cellularity and density of α-SMA reactive material associated with
the stromal cell layers (Fig. 6B). Decreased cellularity of
the tumor cell nests is accompanied by significant tumor
cell rounding and apoptosis as evidenced by nuclear fragmentation shown with DAPI staining (Fig 7A) as well as
positivity for Annexin V binding and cleaved caspase 3
(not shown). In addition to apoptosis, when probed for
PCNA, there was a marked reduction in tumor cell PCNA
and robust staining of PCNA in the stromal cells (Fig. 7A).
Basic flow cytometric evaluation of these cultures demonstrated a 44% reduction in the tumor cell population
within 24 h of treatment with 1 µM Iressa and a >3-fold
increase in the stromal cell population when compared to
control cultures (not shown). When we evaluated the
PCNA, phospho-p44/42 MAPK and phospho-MEK1/2
levels in the ErbB-2 positive and ErbB-2 negative subpopulations we observed a 62%, 54% and 27% reductions in
tumor cell PCNA, phospho-p44/42 MAPK and phosphoMEK1/2, respective (Fig 7B). Interestingly, the larger subpopulation of tumor cells in these treated co-cultures were
approximately 2-fold less responsive to Iressa in terms of
PCNA and phospho-p44/42 MAPK levels attesting to the
transient resistance afforded to cells likely in G2/M (not
shown). In contrast to ErbB-2 positive tumor cells, ErbB-2
negative stromal cells had a robust increase in all of these
proliferation markers following treatment with Iressa.
PCNA levels increased by 205%, phospho-p44/42 MAPK

increased 219% and phospho-pMEK1/2 increased by
279%. These data are in agreement with our qualitative
observations that used immunofluorescence to document
the relative density of the tumor and stroma cell populations in the MAM-1 co-cultures (Fig. 6B). The resilience of
the stromal cell population is not limited to EGFR antagonists. We have also observed that while both the tumor
and stroma cells express comparable levels of the TRAIL
death receptor DR5, only the tumor cells are sensitive to
TRAIL-mediated apoptosis (data not shown). Thus, targeting the stroma to effectively "sterilize" the microenvironment and inhibit tumor growth and progression presents
a major challenge.
Gene expression analysis reveals a signature of the fibrotic
response
To generate a better understanding of the global response
of MAM-1 to Iressa, we compared the gene expression
profiles of MAM-1 co-cultures treated for 24 h with fresh
media containing diluent or 1 µM Iressa. We observed a
strong upregulation of inflammatory genes involved in
the fibrotic response, consistent with the morphology of
the treated MAM-1 co-cultures (Fig. 6A). Interestingly,
none of the genes that were modulated by Iressa in Bam1a
cells [6] were altered in MAM-1. We observed 2.5- to 6fold increases in the expression of genes associated with
inflammatory, fibrotic, pathological processes that are
observed in a variety of diseases [34-37]. Most notably, we
observed increases in inflammatory genes, (C9, CCR7,
TNFRS25, IL1F9, CCL22, TLR8, KLRA23, CLEC4N, CD22),
cell adhesion genes, (COL4A3, SIGLEC5, LGALS12,
CLDN5) growth factor signaling and transcription genes,
(FGF22, CTGF, WNT8A, POU4F3, HEY1) proliferation
and differentiation (CCNB3, MYB, TFF1, PROX1) and
proteolysis genes (GZMK, TLL2, ADAM5, SERPINA1D).

Conclusion
Our data demonstrate the utility of the MAM-1 co-culture
model in understanding the impact of the tumor microenvironment on the differential responses of invasive breast
cancers and tumor associated myofibroblasts to chemotherapeutic agents and therapeutic modalities. Our data
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Effect of Iressa on phosphorylation of p44/42 MAPK by (A) Immunofluorescence and phosphorylation of p44/
42 MAPK and MEK1/2 by (B) flow cytometry in MAM-1 co-cultures. MAM-1 were subcultured on coverslips or in 6well plates and grown to ~95% confluence and then treated by replacing the conditioned media with fresh media that contained diluent (.001% DMSO, Control) or Iressa for 2 hours prior to fixing and evaluation as described in the methods. A.
Immunofluorescent photomicrographs were taken with the indicated objectives of cells that were double labeled for phosphop44/42 MAPK (Thr202/Tyr204) in green (FITC) and α-SMA in red (TRITC) and counterstained with DAPI (blue) to define the
nuclei. B. Dose-response for phosphorylation of p44/42 MAPK and MEK1/2 in MAM-1 co-cultures by flow cytometry. MAM-1
were treated as described above and dual-labeled for ErbB-2 and the indicated phospho-specific antigen. Bars represent Mean
channel fluorescent values for pp44/42 MAPK (Thr202/Tyr204) (Blue Bars) or pMEK1/2 (Ser217/221) (Red Bars) in ErbB2+
(Solid Bars) and ErbB2-(Shaded Bars) subpopulations.
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Figure 6 Effects of Iressa on growth and morphology
Differential
Differential Effects of Iressa on growth and morphology. MAM-1 co-cultures were treated for 24–48 h by replacing
conditioned media with fresh media in the absence (Control) or presence of 1 µM Iressa. A. Phase contrast photomicrographs
of MAM-1 co-cultures following treatment with 1 µM Iressa were taken using a 10× objective. Tumor cell nests (T) decrease in
cellularity over time and stromal cells (S) thicken and increase in cellularity. By 48 h tumor cell nests erode, cells flatten, and
show evidence of apoptosis while stromal cells develop into multi-cell layer nests recapitulating the morphology of a fibrotic
response in vitro. B. Immunofluorescence of MAM-1 that were dual-labeled with HER2/neu-TRITC and α-SMA-FITC to identify the tumor (red) and stromal (green) subpopulations, respectively. Photographs taken under low power (10×) show
decreased cellularity of HER2+ nests (red) and increased cellularity and density in the α-SMA+ stroma (green). These shifts in
the cellularity of the separate subpopulations are emphasized by the nuclear counterstain with DAPI (blue). Under higher magnification (40×) HER2+ nests of tumor cells (red) have decreased in cellularity and flattened into a monolayer while the cellularity and α-SMA reactivity has increased in the stromal elements surrounding the tumor cells generating the thickened
appearance that is associated with fibrosis. Note in particular the membrane accentuation of HER2/neu in the tumor cells
treated with Iressa and the dense bundles of a-SMA reactive fibers in Iressa treated stroma.
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Figure
Effect of Iressa on (A) PCNA activity and (B) Signal transduction in the tumor and stromal cell populations of
MAM-1 co-cultures. A. MAM-1 co-cultures were treated for 24 h with fresh media in the absence (Control) or presence of
1 µM Iressa then fixed and stained with PC10-TRITC to detect PCNA reactivity (red) and counterstained with DAPI to identify
the nuclei (blue) Photomicrographs were taken with the 100× objective under oil immersion. The PCNA index of control
tumor cells is >95% and <12% in the Iressa treated tumor cells. In the stroma adjacent to the Iressa treated tumor nest, PCNA
index is >95%. Note the presence of apoptotic cells in DAPI stained tumor cells treated with Iressa (arrow). B. Differential
effect of Iressa on PCNA, phospho-p44/42 MAPK (Thr202/Tyr204) and phospho-MEK1/2 (Ser217/221) in the ErbB-2 Negative
(Stromal) and ErbB-2 Positive (Tumor) populations in MAM-1 treated for 24 h with 1 µM Iressa. Samples were dual-labeled for
ErbB-2 and the indicated antigen and evaluated by dual-color flow cytometry. Bars represent the Mean Channel Fluorescent
Values for phospho-p44/42 MAPK (Blue Bars), phospho-MEK1/2 (Red Bars) or PCNA (Black Bars). Following Iressa treatment,
the ErbB-2 positive population decreased by 44% and the α-SMA positive population increased 3-fold in these MAM-1 co-cultures.
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suggest that Iressa preferentially targets signal transduction from the tumor cell HER2/neu leading to tumor cell
death and a fibro-proliferative response in the stroma. In
this co-culture model tumor cells retain their intrinsic sensitivity to Iressa and the tumor associated myofibroblasts
of the stroma demonstrate intrinsic resistance to Iressa.
Understanding the tumor regulatory properties of this
microenvironment before, during and after treatment will
be critical in determining the most appropriate treatment
modality to prevent progression and recurrence.
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